Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
information fournie par Boursorama CP 06/11/2025 à 08:30

Computational tool improves recombinant virus design efficiency and yield.

This innovative in-house development is a key component of Transgene’s INTV platform.

Poster to be presented at ESMO-AI 2025


Strasbourg, France, November 6, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announced it will present a poster on its proprietary VacDesignR® computational tool at the upcoming ESMO AI & Digital Oncology 2025 conference, held in Berlin, Germany, from 12-14 November 2025.

.../...

Valeurs associées

TRANSGENE
0,7350 EUR Euronext Paris -0,68%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
73,22 -4,91%
2CRSI
26,6 -3,69%
Or
3 998,45 -0,06%
CAC 40
8 385,49 +0,54%
SPACEX
154,54 -1,01%
Chargement...

Pages les plus populaires

L'offre BoursoBank